Published in Expert Rev Hematol on March 17, 2016
A Safety Study of SGN-CD33A in AML Patients | NCT01902329
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | NCT02326584
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell (2005) 8.37
Acute myeloid leukemia. N Engl J Med (1999) 7.04
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood (2008) 4.66
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood (2010) 4.51
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood (2009) 3.40
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol (2011) 3.34
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 3.09
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood (2009) 2.82
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood (2015) 2.43
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 2.26
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood (2013) 2.12
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma (2010) 1.79
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood (2014) 1.72
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol (2015) 1.69
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol (2015) 1.66
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol (2013) 1.66
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res (2004) 1.59
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol (2015) 1.57
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett (2008) 1.50
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia (2014) 1.38
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia (2012) 1.37
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood (2009) 1.31
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood (2013) 1.31
Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med (2008) 1.27
Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Leukemia (2007) 1.22
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood (2011) 1.21
Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A (2014) 1.12
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell (2002) 1.08
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood (2008) 1.06
Targeting IDH: the next big thing in AML. Blood (2013) 1.04
Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer (2007) 1.02
Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood (2015) 1.01
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica (2003) 0.99
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol (2015) 0.97
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene (2011) 0.96
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol (2012) 0.94
Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma (2013) 0.90
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer (2015) 0.89
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res (2012) 0.87
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer (2014) 0.86
5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs (2010) 0.84
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? Expert Rev Hematol (2016) 0.82
Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Rev Hematol (2015) 0.81
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2013) 0.81
Cell-cycle control during development: taking it up a notch. Dev Cell (2005) 0.81
Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med (2003) 0.80
Emergence of crenolanib for FLT3-mutant AML. Blood (2013) 0.80
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia (2015) 0.79
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Rev Hematol (2014) 0.79
Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets. Expert Rev Hematol (2015) 0.76
Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Rev Hematol (2015) 0.76
Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Rev Hematol (2016) 0.76
Precision medicine for acute myeloid leukemia. Expert Rev Hematol (2015) 0.75
Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Expert Rev Hematol (2016) 0.75